These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 8362270)

  • 1. Coacute heparin: a new simple monotest for monitoring heparin treatment.
    Friberger P; Krig E; Eriksson-Skoog L; Svensson S; Isacson C
    Semin Thromb Hemost; 1993; 19 Suppl 1():86-9. PubMed ID: 8362270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coacute heparin: a new simple monotest for monitoring heparin treatment.
    Friberger P; Urig E; Eriksson-Skoog L; Svensson S; Isacson C
    Semin Thromb Hemost; 1994; 20(4):328-32. PubMed ID: 7899863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective.
    Favaloro EJ; Bonar R; Aboud M; Low J; Sioufi J; Wheeler M; Lloyd J; Street A; Marsden K;
    Lab Hematol; 2005; 11(3):157-62. PubMed ID: 16174600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An improved heparin assay which is insensitive to platelet factor 4.
    Fickenscher K; Buckler U
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):873-8. PubMed ID: 2483705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new chronometric assay to determine plasma antifactor Xa activity which is insensitive to the antithrombin activity of low molecular weight heparins.
    Dignac M; Gabaig AM; Cambus JP; Boneu B
    Nouv Rev Fr Hematol (1978); 1994; 35(6):545-9. PubMed ID: 8152901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
    Kitchen S; Theaker J; Preston FE
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability.
    Kitchen S; Iampietro R; Woolley AM; Preston FE
    Thromb Haemost; 1999 Oct; 82(4):1289-93. PubMed ID: 10544915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P; Boutière B; Horellou MH; Trzeciak MC; Samama MM
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obtaining blood samples for anti-factor Xa quantification through umbilical artery catheters.
    Edstrom CS; McBride J; Theriaque D; Kao KJ; Christensen RD
    J Perinatol; 2002 Sep; 22(6):475-7. PubMed ID: 12168126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monitoring of plasma concentration of low molecular weight heparin--comparative evaluation with chromogenic and clotting assays].
    Katagiri H; Itoh S; Uchida T; Kawai Y; Watanabe K
    Rinsho Byori; 1999 Nov; 47(11):1046-51. PubMed ID: 10590682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring the new antithrombotic drugs.
    Walenga JM; Hoppensteadt DA
    Semin Thromb Hemost; 2004 Dec; 30(6):683-95. PubMed ID: 15630675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor Xa-activated whole blood clotting time (Xa-ACT) for bedside monitoring of dalteparin anticoagulation during haemodialysis.
    Frank RD; Brandenburg VM; Lanzmich R; Floege J
    Nephrol Dial Transplant; 2004 Jun; 19(6):1552-8. PubMed ID: 15034159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The determination of activity of low-molecular heparins against activated factor Xa by means of the diagnostic kit "Reachrom-Heparin" (scientific-production association "Renam")].
    Drozd NN; Makarov VA; Miftakhova NT; Berkovskiĭ AL; Sergeeva EV; Bannikova GE; Varlamov VP
    Patol Fiziol Eksp Ter; 2006; (2):16-8. PubMed ID: 16841652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of lipoprotein lipase activity by tissue factor pathway inhibitor.
    Mukherjee M; Kakkar VV
    Thromb Haemost; 1999 Dec; 82(6):1648-51. PubMed ID: 10613650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
    Fiore MM; Mackie IM
    Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
    Ip BK; Thomson AR; Moriarty HT
    Pathology; 2001 Aug; 33(3):347-52. PubMed ID: 11523938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R; Grebe S
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.